Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study)

Abstract

Diabetic kidney disease (DKD) is a devastating complication that affects an estimated third of patients with type 1 diabetes mellitus (DM). There is no cure once the disease is diagnosed, but early treatment at a sub-clinical stage can prevent or at least halt the progression. DKD is clinically diagnosed as abnormally high urinary albumin excretion rate (AER). We hypothesize that subtle changes in the urine metabolome precede the clinically significant rise in AER. To test this, 52 type 1 diabetic patients were recruited by the FinnDiane study that had normal AER (normoalbuminuric). After an average of 5.5 years of follow-up half of the subjects (26) progressed from normal AER to microalbuminuria or DKD (macroalbuminuria), the other half remained normoalbuminuric. The objective of this study is to discover urinary biomarkers that differentiate the progressive form of albuminuria from non-progressive form of albuminuria in humans. Metabolite profiles of baseline 24 h urine samples were obtained by gas chromatography–mass spectrometry (GC–MS) and liquid chromatography–mass spectrometry (LC–MS) to detect potential early indicators of pathological changes. Multivariate logistic regression modeling of the metabolomics data resulted in a profile of metabolites that separated those patients that progressed from normoalbuminuric AER to microalbuminuric AER from those patients that maintained normoalbuminuric AER with an accuracy of 75% and a precision of 73%. As this data and samples are from an actual patient population and as such, gathered within a less controlled environment it is striking to see that within this profile a number of metabolites (identified as early indicators) have been associated with DKD already in literature, but also that new candidate biomarkers were found. The discriminating metabolites included acyl-carnitines, acyl-glycines and metabolites related to tryptophan metabolism. We found candidate biomarkers that were univariately significant different. This study demonstrates the potential of multivariate data analysis and metabolomics in the field of diabetic complications, and suggests several metabolic pathways relevant for further biological studies.Electronic supplementary materialThe online version of this article (doi:10.1007/s11306-011-0291-6) contains supplementary material, which is available to authorized users.

Associations of Plasma Kynurenines With Risk of Acute Myocardial Infarction in Patients With Stable Angina Pectoris

“…Indeed, Trp metabolism has been hypothesized as a causal mechanism contributing to accelerated atherosclerosis in renal disease. 21,24 Notably, however, adjustment for serum creatinine levels had only minor effects on our risk estimates. Hence, the associations of kynurenines with outcomes seem not solely to reflect pathways activated in renal dysfunction.…”

Metabolomics Reveals Signature of Mitochondrial Dysfunction in Diabetic Kidney Disease

“…To our knowledge, this is the first study to measure the urine metabolome in patients with diabetic kidney disease with a highly quantitative, targeted gas chromatography-mass spectrometry method that has been optimized for urine and used for clinical diagnosis. A recent study from our collaborators 20 studied the association of urine metabolites with progression to albuminuria over a mean follow-up of 5.5 years. Using liquid chromatography-mass spectrometry, they identified hippuric acid to be decreased in the group with progressive disease, and S-(3-oxododecanoyl) cysteamine and acylcarnitines were increased.…”

Obesity and Diabetic Kidney Disease: Role of Oxidant Stress and Redox Balance

“…6). A targeted metabolomics analysis in both experimental models (2,64) and the human condition of diabetes- (35,53,58) and obesity-related kidney disease (13,66,67) will be very useful to unravel in vivo regulation and translation of critical and relevant pathways of renal disease progression.…”